Lichtman, Stuart M.;
Cirrincione, Constance;
Hurria, Arti;
Jatoi, Aminah;
Theodoulou, Maria;
Wolff, Antonio C.;
Gralow, Julie;
Morganstern, Daniel;
Magrinat, Gustav;
Cohen, Harvey Jay;
Muss, Hyman
Effect of renal function (RF) on outcomes in the adjuvant treatment of older women with breast cancer (65 years): CALGB/CTSU 49907 (CC) ancillary data study
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Effect of renal function (RF) on outcomes in the adjuvant treatment of older women with breast cancer (65 years): CALGB/CTSU 49907 (CC) ancillary data study
Beteiligte:
Lichtman, Stuart M.;
Cirrincione, Constance;
Hurria, Arti;
Jatoi, Aminah;
Theodoulou, Maria;
Wolff, Antonio C.;
Gralow, Julie;
Morganstern, Daniel;
Magrinat, Gustav;
Cohen, Harvey Jay;
Muss, Hyman
Erschienen:
American Society of Clinical Oncology (ASCO), 2013
Beschreibung:
<jats:p> 9515 </jats:p><jats:p> Background: CC 49907 showed superiority of standard therapy (cyclophosphamide/doxorubicin [AC] or cyclophosphamide/methotrexate/5-fluorouracil [CMF]) over capecitabine[C]. Dose adjustments made for renal insufficiency (RI) for methotrexate and C; ideal body weight used. Purpose was to analyze the relationship between RF at baseline and 5 endpoints: toxicity, dose modification, therapy completion, relapse-free survival [RFS] and overall survival [OS]. Methods: Pre-treatment RF was calculated (Cockcroft-Gault). Endpoints assessed by regimen. RF was tested as a dichotomous and continuous variable of stages 1,2 vs. 3,4 kidney disease (National Kidney Foundation). Logistic regression modeled the relationship between renal stage and the first three endpoints of toxicity, dose modification and therapy completion. Toxicity divided by hematologic or not. The relationship of RFS and OS with RF was assessed with the logrank test and as a continuous variable with Wald chi square. Results: 619 patients; incidence of stage 3/4 RI(<60 ml/min) was: CMF=72%; AC=64%; C=75%. With AC the incidence of toxicity differed by renal function. 31% of patients with poorer function >grade 3 non-hematologic toxicity vs. 14% with better function(p=0.011). There was a suggestion of effect of RF on OS and RFS for C-treated patients. RF was not associated with dose modification, premature therapy termination, RFS or OS for the CMF-treated patients. Conclusions: 1) AC: declining RF was associated with increased non-hematologic toxicity. 2)Patients with RI who received dose modifications were not at increased risk for complications in comparison to those who did not have renal insufficiency and received full dose. 3)Declining RF did not affect therapy completion. 4)C: suggestion that worse RF was related to poorer RFS or OS. 5)Exclusion of patients from clinical trials with RI based on concern of excessive hematologic toxicity may not be justified with appropriate modification. 6)Results should be considered in the design of clinical trials for older patients. </jats:p>